自1月24日以來,美國食品藥品管理局已與180多家藥品製造商聯繫,並提醒他們其適用的法律要求,以將因冠狀病毒爆發而導致的任何預期供應中斷通知美國食品藥品管理局。
我們還要求他們評估整個供應鏈,在中國製造的活性藥物成分和其他成分。目前,尚無公司報告因COVID19而引起的預期任何藥物短缺的情況。
我們將與製造商保持聯繫,以便我們可以協助他們解決任何潛在的問題。如果美國食品藥品管理局得知藥品供應鏈中的任何弱點或中斷,我們將與製造商一起努力快速緩解因COVID19而引起的任何短缺。
如果發生醫療產品短缺,美國食品藥品管理局將考慮諸多因素,包括與短缺情況相關的公共衛生風險,來決定如何最好地著手應對。
關於美國食品藥品管理局如何應對藥品短缺的更多信息,請查閱我們的網站:https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages#q5
Since January 24, @US_FDA has been reaching out to more than 180 drug manufacturers and reminding them of their applicable legal requirements to notify FDA of any anticipated supply disruptions as a result of the #coronavirus outbreak.
We have also asked them to evaluate their entire supply chain, including active pharmaceutical ingredients and other components manufactured in China. At this time, no firm has reported a shortage is anticipated for any drug due to #COVID19.
We will stay in contact with manufacturers so that we can assist them with any potential issues. Should FDA be made aware of any vulnerabilities or disruptions in the drug supply chain, we will work with manufacturers to quickly mitigate any shortages as a result of #COVID19.
Should a medical product shortage occur, FDA would determine how best to address it, taking into consideration a number of factors, including the public health risk associated with the shortage.
More information can be found on how FDA addresses drug shortages on our website: https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages#q5